Safety monitoring during the first month of the COVID-19 national vaccination program shows “reassuring safety profiles” for the Pfizer and Moderna COVID-19 vaccines, the Centers for Disease Control and Prevention reported today.

Emergency use authorizations for the vaccines require providers to report adverse events to the Vaccine Adverse Event Reporting System. About 91% of VAERS reports between Dec. 14, 2020, and Jan. 13, 2021, were for non-serious events and involved local and systemic symptoms, the authors said. Reported cases of anaphylaxis, a life-threatening but treatable allergic reaction, totaled 4.5 per million doses administered, comparable with those reported for other vaccines, they said.

The 113 deaths reported to VAERS over the period were consistent with expected all-cause mortality and did not suggest a causal relationship with vaccination, the authors said.

Related News Articles

Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…